Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
暂无分享,去创建一个
Pierre Jallon | Eric Renard | Maeva Doron | Brigitte Delemer | G. Charpentier | E. Renard | A. Farret | P. Jallon | A. Penfornis | P. Benhamou | C. Thivolet | M. Joubert | Y. Reznik | D. Raccah | B. Guerci | L. Meyer | N. Jeandidier | S. Franc | V. Melki | L. Chaillous | H. Hanaire | P. Schaepelynck | M. Doron | C. Lukas-Croisier | B. Delemer | Guillaume Charpentier | Bruno Guerci | Yves Reznik | S. Borot | S. Lablanche | Sylvia Franc | Pierre-Yves Benhamou | Charles Thivolet | Pauline Schaepelynck | Lucy Chaillous | Celine Lukas-Croisier | Nathalie Jeandidier | Helene Hanaire | Sophie Borot | Ilham Xhaard | Vincent Melki | Laurent Meyer | Marie Guillouche | Laurene Schoumacker-Ley | Anne Farret | Denis Raccah | Sandrine Lablanche | Michael Joubert | Alfred Penfornis | M. Guillouche | Laurène Schoumacker-Ley | I. Xhaard
[1] E. Racine,et al. A critical review and analysis of ethical issues associated with the artificial pancreas. , 2019, Diabetes & metabolism.
[2] Grant J. Smith,et al. The Use of Continuous Glucose Monitoring With Remote Monitoring Improves Psychosocial Measures in Parents of Children With Type 1 Diabetes: A Randomized Crossover Trial , 2018, Diabetes Care.
[3] R. Beck,et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials , 2018, Diabetes Care.
[4] Janet M. Allen,et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial , 2018, The Lancet.
[5] Y. Bao,et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes , 2018, Diabetes Care.
[6] R. Hovorka,et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis , 2018, British Medical Journal.
[7] G. Charpentier,et al. Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study , 2018, Acta Diabetologica.
[8] Gregory P. Forlenza,et al. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System , 2018, Diabetes Care.
[9] Eyal Dassau,et al. Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia , 2017, Diabetes Care.
[10] Marc D. Breton,et al. Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study , 2017, Diabetes Care.
[11] B. Perkins,et al. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. , 2017, The lancet. Diabetes & endocrinology.
[12] Eyal Dassau,et al. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial , 2017, Diabetes Care.
[13] Ahmad Haidar,et al. Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label, randomised, crossover, controlled trial , 2017, Diabetes, obesity & metabolism.
[14] Roman Hovorka,et al. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study , 2017, The lancet. Diabetes & endocrinology.
[15] Benyamin Grosman,et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes , 2017, Diabetes technology & therapeutics.
[16] Bruce A Buckingham,et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial , 2017, The Lancet.
[17] Bruce W Bode,et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. , 2016, JAMA.
[18] K. Barnard,et al. Toward Development of Psychosocial Measures for Automated Insulin Delivery , 2016, Journal of diabetes science and technology.
[19] Howard C. Zisser,et al. Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report , 2016, Diabetes Care.
[20] Claudio Cobelli,et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.
[21] Roman Hovorka,et al. Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.
[22] David M Maahs,et al. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.
[23] Tadej Battelino,et al. MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial , 2014, Diabetes Care.
[24] D. Klonoff,et al. Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. , 2014, Diabetes technology & therapeutics.
[25] Neil H. White,et al. A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years , 2012, Diabetes Care.
[26] G. Charpentier,et al. The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients , 2011, Diabetes Care.
[27] B. Frier,et al. Frequency of Severe Hypoglycemia in Patients With Type I Diabetes With Impaired Awareness of Hypoglycemia , 1994, Diabetes Care.